

August 12, 2025

To: All Concerned Parties

Solasia Pharma K.K. (Code 4597, TSE, Growth)
Representative: Yoshihiro Arai, President & CEO
Contact: Toshio Miyashita, CFO
Tel: 81-3-5843-8046
URL: <https://solasia.co.jp/en/>

Solasia Announces Licensing Agreement for DARVIAS and episil in Southeast Asia, Oceania, Middle East, and Africa Regions, Sales Approval for episil in Singapore

August 12, 2025 – Solasia Pharma K.K. (TSE: 4597, Headquarter: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announces that has entered into a licensing agreement (the “Agreement”) with FIREBIRD BIOLOGICS PTE LTD (headquartered in Singapore, hereinafter “Firebird”) granting exclusive rights for the sales and distribution of the antitumor drug DARVIAS (generic name: darinaparsin, Solasia development code: SP-02, hereinafter “DARVIAS”) and the medical device episil (intended for the management and relief of oral pain caused by chemotherapy- or radiation therapy-induced oral mucositis; Solasia development code: SP-03, hereinafter “episil”) across 19 countries in Southeast Asia, Oceania, Middle East, and Africa.

Under the terms of the Agreement, a licensing deal has been established to facilitate the commercialisation and marketing of products in the territories of Asia including Australia & New Zealand, the Middle East, and Africa by Firebird Biologics.

Solasia also announces that Firebird Biologics has obtained sales approval for episil from Singapore authorities, started preparations for sales activities, and that product supply from Solasia to Firebird is initiated.

The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to Solasia and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of Solasia. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting Solasia’s actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. The information contained in this press release is for informational purposes only and should not be considered as investment solicitation. Information with regard to pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice. Solasia does not have any obligation to update or revise any information in this press release, and any update or revision may occur anytime without notice.